FCGR3A and follicular lymphoma: This result suggests an important role for CD16 in the mechanism of Elo activity in MM patients, analogous to enhanced ADCC and clinical response to rituximab in follicular lymphoma patients having CD16 158/V/V genotype (53, 54).